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Introduction
IT develops as a result of immune-mediated destruc-
tion of platelets (PLT) by IgG antibodies that interact
with some antigens expressed on their surface (e.g.,
GPIIb-IIIa, GPIa-IIa) [8,9]. Pathogenesis of IT involves
both lymphocytes reactive with PLT specific antigens
[14,15] as well as autoreactive antibodies [16,18]. PLT
covered with antibodies are eliminated by macrophages
in Fc R-dependent mechanism [9]. In addition autoanti-
bodies may also directly suppress megakaryopoiesis in
bone marrow [7,17]. The IT develop both in older pop-
ulation [19] and in children [24].
Microvesicles (MV) are small fragments of cell
membrane between 100 nm to 1 μm in size that are
released by eukaryotic cells during cell membrane
turnover as well as cell activation [5,22]. MV are
present in blood in steady state conditions at a con-
centration of approximately 30 μg/ml. Our group
presented the evidence that PMV can facilitate
hematopoietic stem cells engraftment in myeloablat-
ed recipients [11]. We also showed that PMV could
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Abstract: The pathogenesis and tissue damage that accompanies destruction of platelets in immune thrombocytopenias (IT)
is still not understood very well and in addition to platelets, other cells (e.g. endothelial cells, CD34+ hematopoietic
stem/progenitors) may also become affected. Based on our previous work that platelet antigens (e.g., CD41) may be trans-
ferred by platelet-derived microvesicles (PMV) to the surface of other cells, we asked if platelet derived-antigens, especial-
ly those that are involved in the formation of anti-platelet antibodies in IT (e.g., against antigen HPA1a) could be also trans-
ferred by similar mechanism. To address this issue normal human CD34+ cells, human umbilical vein-endothelial cells
(HUVEC) and monocytic cell line THP-1 were incubated with PMV derived from HPA1a+ donors. We noticed that the
HPA1a antigen is highly expressed on PMV-derived from the HPA1a positive platelets and is transferred in PMV-depend-
ent manner to the surface of CD34+ cells, HUVEC and monocytic THP-1 cells. These cells covered with HPA1a positive
PMV but not by PMV derived from HPA1a negative platelets reacted with anti-HPA1a antibodies derived from the alloim-
munized pregnant women. More importantly, human hematopoietic cells that were preincubated with HPA1a+ PMV and
subsequently exposed to anti-HPA1a serum and human NK cells, become subject to elimination by antibody dependent cell
cytotoxicity ADCC. Thus, we postulate that PMV-dependent transfer of antigens may playing an important role in "expand-
ing" the population of target cells that may be affected by anti-platelet antibodies and explain several pathologies that
accompany IT (e.g. damage of endothelium, cytopenias). 
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stimulate normal and malignant hematopoietic cells
growth and survival [4]. 
Recently, it has been shown that MV can facilitate
immune processes in various systems. It was shown
that melanoma as well as ovarian cancer cell derived
MV can harbor Fas ligand (FasL) on their cell surface.
Both studies in a very elegant way showed that these
MV could actively induce apoptosis of T cells express-
ing Fas receptor [1-3] and thus allow tumor cells to
escape immunosurveillance. Furthermore, we have
demonstrated that PMV may transfer CXCR4 receptor
from PLT to other cells thus improving their homing
after transplantation in bone marrow [11] or even ren-
der CXCR4 negative cells susceptible to HIV infection
[23]. Finally, we showed that PMV may transfer sev-
eral platelet-derived adhesion molecules to the lung
[13] or breast cancer cells [12] and thus increase their
metastatic potential. 
Based on these data we hypothesized that PMV
shed from IT-patient platelets may transfer platelet
derived-antigens (e.g., against antigen HPA1a)
involved in the formation of anti-platelet antibodies to
other cells and thus "expand" the population of target
cells that may be affected by anti-platelet antibodies.
This could explain several pathologies that accompany
IT (e.g. damage of endothelium, cytopenias). 
Materials and methods
PMV preparation. PMV were prepared as described previously
[4]. Briefly, platelets were activated by thrombin (0.1 U/mL) and
collagen (4 μl/mL) for 30 min at 37°C with stirring. After activa-
tion platelets were centrifuged 2 times at 3000 pm (2000 g) for 15
min at 4°C and the PMV-enriched supernatants were collected.
Supernatants were again centrifuged at 28000 g for 1 h at 4°C.
PMV were washed and finally resuspended in Hepes buffer,
pH=7.4. Quality of every PMV preparation was checked by flow
cytometry analysis using phycoerythrin (PE)-conjugated anti-
human antibodies against CD41 (Coulter-Immunotech, Marseille,
France).
Isolation of human CD34+ and human endothelial cells. Bone
marrow samples were obtained according to procedures approved
by Institutional Bioethics Committee. Light-density mononuclear
cells (MNC) were separated by Ficoll-Isopaque density gradient
centrifugation at 400 g for 30 minutes at room temperature. MNC
were washed twice with PBS and CD34+ cells were isolated by
immunoaffinity selection with MiniMACS paramagnetic beads
(Miltenyi Biotec, Germany) according to manufacturer's protocol.
Briefly, cells were resuspended in isolation buffer and incubated
for 30 minutes at 4°C with anti-human CD34 monoclonal antibody
conjugated with microbeads, in a presence of FcR-blocking
reagent. Labeled cells (CD34+) were enriched on columns in the
magnetic field. Unlabelled cells were washed out and after removal
of the column from magnetic field CD34+ cells were eluted with
the plunger.
Human umbilical vein endothelial cells (HUVEC) were isolat-
ed from umbilical vein using collagenase I (Sigma) digestion and
propagated in M199 medium supplemented with 10% fetal calf
serum, 1 mg/mL bovine brain extract, 1 ng/mL human epidermal
growth factor, 1 mg/mL hydrocortisone, 10 U/mL heparin (all
reagents from Sigma).
Binding and detection of PMV. Binding of HPA1a+ PMV to tar-
get cells was evaluated using flow cytometry (THP1, CD34+ cells)
and immunofluorescent staining (endothelial cells). Nonadherent
and adherent cells were incubated with PMV for 10 min to 2 h at
37°C in the presence of 2 mM CaCl2 and nonadherent cells were
washed twice at 1000 rpm (210 g) for 5 min to remove unbound
platelets, the resulting cell pellets were resuspended in PMV bind-
ing buffer. Cover slips with adherent cells were washed three
times. Next cells were incubated in presence of serum containing
anti HPA1a antibodies at 1:4 dilution with PMV binding medium.
Finally, cells were washed once or twice, resuspended in PBS and
incubated with anti-human IgG FITC conjugated antibodies
(DakoCytomation) to detect presence of HPA1a on the surface of
target cells or with control anti-CD 41 MoAb (BD Sciences). 
Cell proliferation by MTT Assay. The MTT assay was performed
according to the manufacturer's recommendations (Promega).
Briefly, THP1 cells were seeded in 96-well plates at 104/well in
DMEM medium containing different dilutions of HPA1a+PMV or
HPA1a-PMV serum (1/2, 1/4, 1/8, 1/16, 1/32). After 72 h 20 µl of
CellTiter 96 Aqueous One Solution reagent were added to each
well and plates were incubated for 3-4 h. Subsequently, plates were
read at 490 nm using the ELx800 Universal Microplate Reader
(Bio-tech) and analyzed with KC4 v3.0 with PowerReports soft-
ware.
Cytotoxicity assay. Target cells (THP-1) were labeled with 1mM
of Calcein AM in RPMI at 37°C for 20 min and washed twice with
PBS. Labeled cells were incubated with HPA1a+ PMV for 10 min
to 2 h washed and incubated with serum containing anti-HPA1a
antibodies. Cells were washed and incubated with the population
of NK effector cells (human YT cell line) for 4 hours at several
ratios (1:10, 1:25, 1:50 and 1:100). Dead cells were scored by
FACS after propidium iodide staining.
CFU-GM colony formation. 0.2 × 104 CD34+ cells were resus-
pended in 0.2 ml IMDM medium (Sigma Chemicals) containing 10
ng/ml IL-3 and 5 ng/ml GM-CSF. Subsequently 0.9 ml of
Methocult medium (Stem Cells Technologies) containing growth
factors was added, mixed gently and then plated in duplicate on 24-
well culture plates (0.5 ml/well). Cultures were incubated at 37°C
in fully humidified atmosphere supplemented with 5% CO2.
Colony-forming units-granulocyte-macrophage (CFU-GM) were
identified and counted using an inverted microscope after 14 days
of culture. 
Statistical analysis. Statistical analysis of the data was performed
with Origin 5.0 using the Mann-Whitney test, with p<0.05 consid-
ered significant.
Results
Binding of HPA1ave+PMV to hematopoietic and
endothelial cells
We have shown before that several antigens, including
integrins and chemokines receptors, present on
platelets surface can be transferred between PLT and
other cells by PMV [1,11,23]. Here we evaluated if
HPA1a antigen, that is involved in generation of PLT-
destructing response could be also transferred by PMV
to other cells such as normal human CD34+ cells,
human umbilical vein-endothelial cells (HUVEC) and
monocytic (THP-1) cell line. 
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In the first set of experiments THP-1 cells were
incubated with PMV derived from HPA1a positive and
negative platelets followed by incubation with HPA1a
reactive serum from the alloimmunized pregnant
women. The binding of anti-HPA1a immunoglobulins
to cells preincubated with PMV were detected with
FITC-conjugated anti-IgG Ab. As a control for equal
binding of HPA1a positive and negative PMV we used
staining with anti-CD41 MoAb. We noticed that the
HPA1a antigen was highly expressed on PMV and was
easily transferred to the surface of target cells in PMV
dependent manner. PMV detection was highly specific
because HPA1a antigen was only detected on the cells
that were incubated with HPA1a positive PMV (Fig.
1C) and cells covered by PMV derived from HPA1a
negative platelets did not bind anti-HPA1a antibodies
(Fig. 1B). In control experiments both types of PMV
transferred efficiently CD41 to the surface of the target
cells (Fig. 1D). 
Since HPA-1a antigen could be transferred by PMV
to the other cells, we hypothesized that it could be also
transferred to human CD34+ cells. This could lead to
destruction of CD34+ stem/progenitor cells by anti-
HPA-1a binding antibodies and thus contribute to the
cytopenias which are seen in IT patients. To address
this issue human bone marrow or cord blood derived
CD34+ cells were incubated with HPA1a+ PMV and
exposed to HPA1a reactive serum from the alloimmu-
nized pregnant women. We found that highly purified
CD34+ cells were easily covered with PMV as evi-
denced by binding of anti-HPA1a serum (Fig. 2). This
data suggests that CD34+ cells could be a potential tar-
get for immune responses directed against platelet
antigens.
Similar PMV-dependent mechanism could also
contribute to destruction of endothelium in IT patients.
To check this hypothesis that PMV may transfer
immunoreactive HPA-1a to the endothelial cells we
incubated HUVEC with HPA1a+ PMV and subse-
quently exposed these cells to anti-HPA1a serum. By
employing immunofluorescence microscope we con-
firmed PMV-mediated transfer HPA1a+ to HUVEC
(Fig. 3A). Again binding of anti-HPA1a Ab was very
specific and anti-HPA1a serum did not bind to
HUVEC incubated with HPA1a negative PMV (Fig.
3B). However binding of both HPA1a positive and
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Fig. 1. Binding of HPA1a positive PMV to THP-1 and TF-1 cells. Detection of HPA1a+ PMV and HPA1a- PMV on monocytic THP-1
cells (A) - cells only, (B) - HPA1a negative PMV, (C) - HPA1a positive PMV, (D) - positive control. Experiment was repeated 2 times
with similar results. Representative data are shown.
Fig. 2. Binding of HPA1a positive PMV to CD34+ cells. A. Cytogram of CD34 positive cells. B. Detection of HPA1a antigen on CD34
incubated with anti-HPA1a serum and anti-human FITC conjugated Ab in absence of PMV. C. Detection of HPA1a antigen on CD34 cells
preincubated with HPA-1a+ PMV and than exposed to anti-HPA1a serum followed by anti-human FITC conjugated Ab. Experiment was
repeated 3 times with similar results. Representative data are shown.
negative PMV was similar as assessed by level of
CD41 antigen (data not shown). 
HPA1a positive PMV render hematopoietic cells
susceptible to immune responses
To address if PMV-transferred antigens can activate
the immune responses to platelet antigens, we focused
on activation of an Ab-dependent response that
involves activation of complement cascade (Fig. 4A)
as well as NK cell-mediated cellular response (Fig.
4B) to THP-1 cells covered or not-covered with PMV. 
We noticed a significant decrease in THP-1 cell
proliferation covered by HPA-1+ PMV after expo-
sure to reactive serum being both source of antibod-
ies and complement proteins (Fig. 4A). Similarly
viability of THP-1 cells covered by HPA-1+ PMV
was decreased in a presence of NK cell line YT as
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Fig. 3. Binding of HPA1a positive PMV to endothelial cells. A. Detection of HPA1a antigen on endothelial cells. HUVEC were incubat-
ed with HPA1a+ PMV, washed and incubated with anti-HPA1a positive serum. Next, cells were washed again and anti-HPA1a antibodies
were detected with anti-human IgG FITC conjugated Ab ( HPA-1a+ve serum). B.  Detection of HPA1a antigen on endothelial cells was
performed as in panel A except for the use of anti-HPA negative serum ( HPA-1a-ve serum). Experiment was repeated 2 times with sim-
ilar results. Representative data are shown.
Fig. 4. ADCC assay with target
cells coated with HPA1a positive
PMV. A. THP-1 cells were incubat-
ed with HPA1a+ PMV and subse-
quently with anti-HPA positive or
negative serum (control). Prolifera-
tion of THP-1 cells was measured
with MTT assay after 72 hours of
incubation. Data from 2 independ-
ent experiments are pooled togeth-
er; * p<0.05. B. THP-1 target cells
coated with HPA-1a positive PMV
were incubated with YT NK effector
cell line in a presence or absence of
HPA-1a positive serum. Data from 2
independent experiments are pooled
together; * p<0.05. C.  CD34+ cells
were coated with HPA1a+ PMV and
exposed to anti-HPA positive (n-2)
or negative serum (n-2). CFU-GM
colonies were scored after 11 days
using inverted light microscope.
Number of CFU-GM colonies
/2×104plated cells is shown; 
* p<0.05. (A-C) each data is repre-
sented as a separate box. The hori-
zontal lines in the box denote the
25th and 75th percentile values.
The error bars denote the 5th and
95th percentile values. The square
symbol in the box denotes the mean
of data.
evidenced by an increase in number of PI positive
cells which prior to cytotoxic assay were covered by
HPA-1+ PMV (Fig. 4B).
Because we noticed that PMV transferred HPA-1
antigen to CD34+ cells (Fig. 2) we looked at the influ-
ence of anti HPA-1 serum on CD34+ cells colony for-
mation. Accordingly, CD34+ cells were coated with
HPA-1+ PMV and exposed to YT cells in a presence of
anti HPA-1- or control serum. We noticed significant
decrease of CFU-GM colony formation by CD34+
cells which were covered by HPA-1+ PMV and subse-
quently exposed to anti HPA-1 serum (Fig. 4C). 
Discussion
PMV play an important role in intercellular crosstalk
and as reported they may (i) stimulate target cells
directly by surface-expressed ligands acting as a kind
of "signaling complex" [22], (ii) transfer surface
receptors from one cell to another [4,11,23], (iii) deliv-
er proteins, mRNA, bioactive lipids into target cells
[4,21], and finally, (iv) serve as a vehicle ("Trojan
horse" mechanism) to transfer infectious particles
between cells (e.g., HIV or prions) [10,20,23]. Here
we describe for the first time evidence that PMV may
transfer immune-reactive antigen HPA-1a from the
platelets to the membranes of hematopoietic cells. We
postulate that this mechanism may play an underap-
preciated role in pathogenesis of IT-related cytopenias
as well as in endothelium damage.
Evidence accumulates that the decrease in platelet
count that is seen in IT patients is related to (i) clear-
ance of IgG covered- PLT by immune system and (ii)
damage of megakaryocytes [7,17]. It is well docu-
mented that the HPA-1a antigen expressed on the sur-
face of the platelets may trigger an immune response
that lead to the formation of anti-HPA-1a immuno-
reactive antibodies [6]. However, the exact mecha-
nisms that lead to the tissue damage and cytopenias in
IT patients are still unknown. In this paper we provide
an evidence that hematopoietic cells covered by PMV
bearing IT-related antigen HPA1a may bind anti-
HPA1a immunoreactive antibodies and thus become a
target for destruction by humoral (complement
dependent) and cellular (NK dependent) immune
mechanisms. 
The fact that PMV transferred HPA1a antigen to
the surface of the target cells is in agreement with our
earlier data showing that several antigens expressed on
platelet membranes (e.g, CD41 or CXCR4) could be
transferred by PMV from platelets to the surface of
normal and malignant hematopoietic cells as well as to
the cancer cells [4,11-13,23]. We reported that platelet-
derived surface molecules transferred to the target
cells may play an important role in regulating adhesion
of these cells [4,11] and susceptibility for HIV infec-
tion [23]. This supports a concept that platelet-derived
surface molecules are functional after transfer and
incorporation to the membranes of the target cells.
This assumption is relevant for our study because in
order to trigger the immune response, PMV-trans-
ferred HPA1a antigen has to be properly expressed on
the target cells - what is required for its recognition
and binding by the anti-HPA1a specific antibodies. 
In order to demonstrate that cells that express
PMV-derived HPA1a could trigger immune response
we employed two different models. In the first model
we showed that anti-HPA-1 Ab may trigger immune
reaction against target cells by employing Ab-mediat-
ed complement-dependent response. In the second one
the same Abs triggered NK-cell mediated cytotoxicity. 
These results in overall suggests that in addition to
observed destruction/elimination of platelets in IT
patients, an underappreciated and important role in
pathogenesis of this disorder may also play damage of
both vascular endothelium and pool of hematopoietic
CD34+ stem/progenitor cells due to the transfer of
platelet-related immune-reactive antigens by PMV.
The clinical significance of this phenomenon is cur-
rently studied in our laboratories.
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